Adults 18 to 60, any sex, with Acute Myeloid Leukemia or Acute Lymphoid Leukemia. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
The Percent of Subjects Engrafting by Day +30 After TransplantationPrimary· Day 0 to Day +30 post transplant
Percent of patients and the 95% Binomial Confidence interval who were able to achieve neutrophils engraftment (defined as the date of the first of three consecutive ANC values obtained on different days after transplantation during which the absolute neutrophils count (ANC) is at least 0.5 x109/l) by 30 days following transplant.
Group
Value
95% CI
Sitagliptin
100
78 – 100
Time to Neutrophil EngraftmentSecondary· Transplant (Day 0) up to 1 year
Time to neutrophil engraftment will be analyzed by the Kaplan-Meier method. The time to engraftment of neutrophils is defined as the time from day 0 to the date of the first of three consecutive days after transplantation during which the absolute neutrophils count (ANC) is at least 0.5 x109/l. Patients surviving at least 14 days after transplant will be evaluable for this endpoint. Patients who did not have neutrophil engraftment before death will be censored at the date of death. The median and 95% confidence intervals will be provided.
Group
Value
95% CI
Sitagliptin
19
13 – 20
Time to Platelet EngraftmentSecondary· Transplant (Day 0) up to 1 year
Time to platelet engraftment will be analyzed by the Kaplan-Meier method. The time to engraftment of platelets is defined as the time from day 0 to the first of three consecutive Complete Blood Counts (CBCs) obtained on different days after transplantation during which the platelet count is at least 20 x109/l. The CBCs obtained should be at least seven days after the most recent platelet transfusion. Only patients who achieved engraftment of platelets will be included in the analysis. The median and 95% confidence intervals will be provided.
Group
Value
95% CI
Sitagliptin
52
21 – 89
Number of Subjects With Treatment Related Adverse Events Grade 3 and 4 Non-hematological ToxicitiesSecondary· Day 0 up to 3 years
Number of unique patients who had a treatment related (possible, probable or definite) non-hematological adverse event that was graded 3 or greater.
Group
Value
95% CI
Sitagliptin
0
Adverse events — posted to ClinicalTrials.gov
Time frame: Up to 3 years.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Sitagliptin
Serious: 9/15 (60%)
Deaths: —
Serious adverse events (20 terms)
Reaction
System
Sitagliptin
Infections and infestations - Other
Infections and infestations
—
Multi-organ failure
General disorders
—
Sepsis
Infections and infestations
—
Respiratory failure
Respiratory, thoracic and mediastinal disorders
—
Cardiac arrest
Cardiac disorders
—
Colitis
Gastrointestinal disorders
—
Oral pain
Gastrointestinal disorders
—
Hepatitis viral
Infections and infestations
—
Meningitis
Infections and infestations
—
Acidosis
Metabolism and nutrition disorders
—
Anorexia
Metabolism and nutrition disorders
—
Dehydration
Metabolism and nutrition disorders
—
Hydrocephalus
Nervous system disorders
—
Acute kidney injury
Renal and urinary disorders
—
Adult respiratory distress syndrome
Respiratory, thoracic and mediastinal disorders
—
Hypoxia
Respiratory, thoracic and mediastinal disorders
—
Pharyngeal mucositis
Respiratory, thoracic and mediastinal disorders
—
Pulmonary edema
Respiratory, thoracic and mediastinal disorders
—
Respiratory, thoracic and mediastinal disorders - Other
The main purpose of this trial is to assess the efficacy and safety of sitagliptin in enhancing engraftment following umbilical cord blood transplantation (recovery of blood counts after transplant).
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07417618 — INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)
· active not recruiting
NCT07390110 — Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejectio
· active not recruiting
NCT06851962 — Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.
· Phase 4
· active not recruiting
NCT06246799 — Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes
· Phase 3
· recruiting
NCT06659718 — Emulation of the SOUL Diabetes Trial in Healthcare Claims
· completed
Other recruiting trials for Acute Myeloid Leukemia
Currently open trials in the same condition.
NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa
· Phase 1
· recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I
· Phase 2
· recruiting
NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML
· Phase 1
· recruiting
NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod
· Phase 1
· recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes
· Phase 1
· recruiting
Other Sherif S. Farag trials
Trials by the same sponsor.
NCT02683525 — Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
· Phase 2
· completed
NCT02589860 — Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant
· withdrawn
NCT02078102 — A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
· Phase 2
· completed
NCT01303965 — Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)
· Phase 1, PHASE2
· terminated
NCT00593554 — Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
· Phase 2
· terminated
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sherif S. Farag
Last refreshed: 8 January 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01720264.